NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

肥厚性心肌症:開發中產品分析

Hypertrophic Cardiomyopathy (Cardiovascular) - Drugs In Development, 2021

出版商 Global Markets Direct 商品編碼 361623
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
肥厚性心肌症:開發中產品分析 Hypertrophic Cardiomyopathy (Cardiovascular) - Drugs In Development, 2021
出版日期: 2021年08月30日內容資訊: 英文 116 Pages
簡介

肥厚性心肌症(HCM)是心肌異常肥大的疾病。心肌一旦變得肥厚便難以將血液送出心臟。症候有特別在運動時會感到胸部疼痛,心搏變快且不穩定,愈來愈激烈,有雜音。肥厚性心肌症通常是遺傳性。治療有使用β受體阻斷劑,鈣離子阻斷劑,抗凝血劑等。

本報告提供肥厚性心肌症的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

肥厚性心肌症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

肥厚性心肌症的治療藥開發企業

  • Gilead Sciences, Inc.
  • Heart Metabolics Limited
  • Lead Discovery Center GmbH
  • MyoKardia, Inc.

藥物簡介

肥厚性心肌症:暫停中的計劃

肥厚性心肌症:開發中止的產品

肥厚性心肌症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC13061IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2021, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 3, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Hypertrophic Cardiomyopathy - Overview
  • Hypertrophic Cardiomyopathy - Therapeutics Development
  • Hypertrophic Cardiomyopathy - Therapeutics Assessment
  • Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
  • Hypertrophic Cardiomyopathy - Drug Profiles
  • Hypertrophic Cardiomyopathy - Dormant Projects
  • Hypertrophic Cardiomyopathy - Discontinued Products
  • Hypertrophic Cardiomyopathy - Product Development Milestonesh
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Hypertrophic Cardiomyopathy, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Algomedix Inc, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by BioMarin Pharmaceutical Inc, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Bristol-Myers Squibb Co, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by C&C BioPharma LLC, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Cardior Pharmaceuticals GmbH, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Celltrion Inc, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Cytokinetics Inc, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Genome Biologics UG, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Haya Therapeutics SA, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Igia Pharmaceuticals Inc, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Imbria Pharmaceuticals Inc, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by LEXEO Therapeutics LLC, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Novartis AG, 2021
  • Hypertrophic Cardiomyopathy - Pipeline by Toa Eiyo Ltd, 2021
  • Hypertrophic Cardiomyopathy - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hypertrophic Cardiomyopathy, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021